Valuation: Scancell Holdings plc

Market Cap 97.55M 130M 114M 106M 183M 12.45B 186M 1.26B 493M 6.15B 487M 477M 21.24B P/E 2026 *
-6.28x
P/E 2027 * -11.9x
Enterprise Value 108M 144M 126M 118M 203M 13.78B 205M 1.4B 546M 6.8B 539M 528M 23.51B EV / Sales 2026 *
86.4x
EV / Sales 2027 * 47.3x
Free-Float
96.34%
Yield 2026 *
-
Yield 2027 * -
1 day+2.55%
1 week-28.59%
Current month-44.91%
1 month-42.45%
3 months-25.85%
6 months-25.13%
Current year-2.63%
1 week 9.3
Extreme 9.3
14
1 month 9.3
Extreme 9.3
18.5
Current year 9.3
Extreme 9.3
29.5
1 year 7.86
Extreme 7.8555
29.5
3 years 7.26
Extreme 7.26
29.5
5 years 7.26
Extreme 7.26
29.5
10 years 0.11
Extreme 0.1118
29.5
Manager TitleAgeSince
Chief Executive Officer 69 27/07/2021
Chief Executive Officer 64 17/11/2024
Director of Finance/CFO 50 23/04/2026
Director TitleAgeSince
Director/Board Member 69 16/11/2010
Director/Board Member 74 22/10/2019
Director/Board Member 64 23/09/2020
Date Insider Type Main position Quantity % Market Cap.
16/09/25
Vulpes Investment Management Pte Ltd.
BuyCompany 3,150,000 0.3038%
08/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 102,236 0.0099%
04/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 4,400,000 0.4244%
Change 5-day change 1-year change 3-year change Capi.($)
+2.55%-28.59%-1.13%+4.22% 130M
+2.08%-0.99%-1.03%+11.57% 46.86B
-0.60%+4.30%+404.94%+647.48% 40.23B
+0.41%+5.75%+11.52%+56.77% 36.23B
+1.83%+3.91%+7.14%-5.65% 34.72B
+0.62%+1.65%+5.41%+43.89% 27.89B
-0.66%+13.08%+31.76%+139.86% 16.79B
+0.41%+1.28% - - 16.74B
+0.78%-5.88%+2.29%+7.76% 13.12B
+2.00%+1.92%-10.70%-29.91% 12.7B
Average +0.93%-2.04%+50.02%+97.33% 24.54B
Weighted average by Cap. +0.78%+1.04%+76.47%+138.82%

Financials

2026 *2027 *
Net sales 1.25M 1.66M 1.46M 1.36M 2.35M 160M 2.38M 16.18M 6.32M 78.76M 6.24M 6.11M 272M 2.4M 3.19M 2.81M 2.61M 4.51M 306M 4.57M 31.06M 12.13M 151M 11.99M 11.73M 523M
Net income -19.23M -25.59M -22.5M -20.94M -36.12M -2.45B -36.59M -249M -97.23M -1.21B -96.07M -94M -4.19B -8.24M -10.96M -9.64M -8.97M -15.47M -1.05B -15.67M -107M -41.64M -519M -41.14M -40.26M -1.79B
Net Debt 10.42M 13.86M 12.18M 11.34M 19.56M 1.33B 19.82M 135M 52.66M 656M 52.03M 50.91M 2.27B 15.87M 21.12M 18.57M 17.29M 29.81M 2.03B 30.2M 205M 80.24M 1B 79.29M 77.58M 3.46B
Logo Scancell Holdings plc
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.
Employees
60
Date Price Change Volume
27/07/26 GBX 9.640 +2.55% 19,137,685
24/07/26 GBX 9.400 -10.48% 21,654,800
23/07/26 GBX 10.50 -17.65% 18,012,510
22/07/26 GBX 12.75 -5.56% 1,344,509
21/07/26 GBX 13.50 0.00% 686,674
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0940GBP
Average target price
0.2550GBP
Spread / Average Target
+171.28%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCLP Stock